Cilcare is a US–French biotech company pioneering auditory sciences to advance the detection and treatment of hearing disorders, now recognized as the leading modifiable risk factor for dementia.

Its lead compound, CIL001, is a first-in-class small molecule, disease-modifying drug candidate targeting cochlear synaptopathy — a condition responsible for difficulty understanding speech in noisy environments and considered an early marker of age-related hearing loss. This disorder affects 15% of the global population, is exacerbated by noise exposure, and is among the main causes of tinnitus and hyperacusis.

CIL001 is expected to enter Phase 2a clinical trials in the US and EU in 2026.

Cilcare secured a $40m Series A financing in December 2024, with Shionogi Ltd joining as a strategic investor. We are now expanding our drug pipeline and seeking an additional $50m to advance two new compounds into the clinic within the next 24 months and expand its footprint in Japan.